ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
Low Transmission Rate of Hepatitis E Virus by Transfusion of Hepatitis E Virus RNA-Positive Blood Products.
Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Viral Safety of Blood Products: Beyond HBV, HCV, and HIV.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatitis E virus (HEV) can cause transfusion-transmitted (TT) infections. Therefore, in many countries, blood donor screening for HEV RNA has been established. The amount of infectious HEV RNA concentration in blood donations and screening strategy (pool size, single-sample testing) are still debated. Methods: Blood donations, taken before the universal blood donor screening for HEV RNA, were investigated retrospectively for HEV RNA. Recipients of an HEV RNA-positive blood product were traced by look-back procedure. Archive samples of these recipients were investigated for TT-HEV infection by HEV RNA and anti-HEV IgG testing. HEV RNA concentration in the donor and in the transfused blood product was determined. Results: In 85/75,905 donations (0.1%), HEV RNA was detectable. A total of 28 recipients of 139 blood products from these donations could be further investigated. In 2/28 (7.1%) recipients, a possible TT-HEV infection occurred, but sequence analysis between donor and recipient could not be performed. HEV RNA concentration could be determined in 23 blood products and ranged from 10.9 IU/mL to 116,400 IU/mL donor plasma and absolute 120 IU-8,748,000 IU in the final blood product. In the cases of possible TT-HEV infection, HEV RNA concentration was 62,880 IU/mL donor plasma, according to 691,680-943,200 in the red blood cell concentrate and 593 IU/mL donor plasma, according to 8,302-11,267 IU in the pooled platelet concentrate. Conclusion: Only a minority of HEV RNA-positive blood products caused a TT-HEV infection. With the limitation of the low number of investigated cases, even in blood products, which were contaminated with extremely high HEV RNA concentrations, there was no evidence for TT-HEV infection. Blood donor screening for HEV RNA by pooled samples should be favored over single-sample testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.